Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gisela Soboll Hussey has a total of 161 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Characterization of EHV-1 viral genes at the respiratory tract using a tracheal explant culture model.

    by Glorián Berríos Vázquez, Kim S. Giessler, Swati Sharma, Nikolaus Osterrieder, Matti Kiupel, Walid Azab, Gisela Soboll Hussey

  • Open Access

    Equine herpesvirus-1 molecular prevalence and serological status of healthy broodmares in southern ontario

    by Carina J Cooper, Gisela Soboll Hussey, Jutta D Hammermueller, David L Pearl, Luis G Arroyo, Brandon N Lillie

  • Open Access

    EQUINE HERPESVIRUS-1 MOLECULAR PREVALENCE AND SEROLOGICAL STATUS OF HEALTHY BROODMARES IN SOUTHERN ONTARIO

    by Carina J. Cooper, Gisela Soboll Hussey, Jutta D. Hammermueller, David L. Pearl, Luis G. Arroyo, Brandon N. Lillie

    Equine herpesvirus-1 is associated with abortion, respiratory disease and myeloencephalopathy. Vaccination is used to mitigate diseases and limit virus spread, but the serological status of Ontario’s broodmare population or the response to vaccination is unknown. We hypothesize that broodmares have a high anti-EHV-1 titres due to vaccination and exposure, but titres are not affected by pregnancy status. Sera were collected from 381 healthy broodmares from 42 Ontario farms bi-monthly from December 2016 through October 2017. Blood, nasal, and vaginal swab samples for EHV-1 droplet digital PCR analysis were also collected every two months, as well as demographic surveys and vaccination information. Serology was assessed using virus neutralization and ELISA for IgGa (IgG1), IgGb (IgG4/7), and IgG(T) (IgG3/5). Titers significantly varied by breed/breed group, but differences varied by serological measure. Titers increased with age but were not affected by pregnancy status. Most mares had EHV-1 specific IgG and virus neutralizing (VN) titers but 32.3% did have neutralizing titers < 1:512, and 42.1 % of vaccinated mares had no biologically significant changes in their neutralizing titers during the study period. IgG subisotype levels varied with the vaccine product, but not in a consistent pattern across subisotypes. No IgG subisotype was significantly associated with EHV-1 detection. Vaccination was associated with increased titers regardless of type of vaccine used, no vaccine product produced a consistent immune response and a fraction of mares did not respond to commercial vaccines despite regular vaccination, and titer levels were not predictive of EHV-1 detection.

  • Open Access

    IFNL3 reduces replication of CIRDC-associated viruses in canine airway epithelial cells

    by Swati Sharma, Glorián Berríos-Vázquez, Kennedy Baldwin, Roger Maes, Gisela Soboll Hussey

  • Open Access

    Impact of the host immune response on the development of equine herpesvirus myeloencephalopathy in horses

    by K. S. Giessler, L. S. Goehring, S. I. Jacob, Allison Davis, M. M. Esser, Y. Lee, L. M. Zarski, P. S. D. Weber, G. S. Hussey

    Herpesviruses establish a well-adapted balance with their host’s immune system. Despite this co-evolutionary balance, infections can lead to severe disease including neurological disorders in their natural host. In horses, equine herpesvirus 1 (EHV-1) causes respiratory disease, abortions, neonatal foal death and myeloencephalopathy (EHM) in ~10 % of acute infections worldwide. Many aspects of EHM pathogenesis and protection from EHM are still poorly understood. However, it has been shown that the incidence of EHM increases to >70 % in female horses >20 years of age. In this study we used old mares as an experimental equine EHV-1 model of EHM to identify host-specific factors contributing to EHM. Following experimental infection with the neuropathogenic strain EHV-1 Ab4, old mares and yearling horses were studied for 21 days post-infection. Nasal viral shedding and cell-associated viremia were assessed by quantitative PCR. Cytokine/chemokine responses were evaluated in nasal secretions and cerebrospinal fluid (CSF) by Luminex assay and in whole blood by quantitative real-time PCR. EHV-1-specific IgG sub-isotype responses were measured by ELISA. All young horses developed respiratory disease and a bi-phasic fever post-infection, but only 1/9 horses exhibited ataxia. In contrast, respiratory disease was absent in old mares, but all old mares developed EHM that resulted in euthanasia in 6/9 old mares. Old mares also presented significantly decreased nasal viral shedding but higher viremia coinciding with a single fever peak at the onset of viremia. According to clinical disease manifestation, horses were sorted into an EHM group (nine old horses and one young horse) and a non-EHM group (eight young horses) for assessment of host immune responses. Non-EHM horses showed an early upregulation of IFN-α (nasal secretions), IRF7/IRF9, IL-1β, CXCL10 and TBET (blood) in addition to an IFN-γ upregulation during viremia (blood). In contrast, IFN-α levels in nasal secretions of EHM horses were low and peak levels of IRF7, IRF9, CXCL10 and TGF-β (blood) coincided with viremia. Moreover, EHM horses showed significantly higher IL-10 levels in nasal secretions, peripheral blood mononuclear cells and CSF and higher serum IgG3/5 antibody titres compared to non-EHM horses. These results suggest that protection from EHM depends on timely induction of type 1 IFN and upregulation cytokines and chemokines that are representative of cellular immunity. In contrast, induction of regulatory or TH-2 type immunity appeared to correlate with an increased risk for EHM. It is likely that future vaccine development for protection from EHM must target shifting this ‘at-risk’ immunophenotype.


  • Top Cited Papers
    Open Access

    Updated ACVIM consensus statement on equine herpesvirus-1

    by David P. Lunn, Brandy A. Burgess, David C. Dorman, Lutz S. Goehring, Peggy Gross, Klaus Osterrieder, Nicola Pusterla, Gisela Soboll Hussey

    Equine herpesvirus-1 (EHV-1) is a highly prevalent and frequently pathogenic infection of equids. The most serious clinical consequences of infection are abortion and equine herpesvirus myeloencephalopathy (EHM). The previous consensus statement was published in 2009 and considered pathogenesis, strain variation, epidemiology, diagnostic testing, vaccination, outbreak prevention and control, and treatment. A recent survey of American College of Veterinary Internal Medicine large animal diplomates identified the need for a revision to this original consensus statement. This updated consensus statement is underpinned by 4 systematic reviews that addressed key questions concerning vaccination, pharmaceutical treatment, pathogenesis, and diagnostic testing. Evidence for successful vaccination against, or effective treatment of EHV-1 infection was limited, and improvements in experimental design and reporting of results are needed in future studies of this important disease. This consensus statement also updates the topics considered previously in 2009.


  • Open Access

    Pharmacologic interventions for the treatment of equine herpesvirus-1 in domesticated horses: A systematic review

    by Lutz Goehring, David C. Dorman, Klaus Osterrieder, Brandy A. Burgess, Kelsie Dougherty, Peggy Gross, Claire Neinast, Nicola Pusterla, Gisela Soboll-Hussey, David P. Lunn

    Background: Equine herpes virus type 1 (EHV-1) infection in horses is associated with upper respiratory disease, neurological disease, abortions, and neonatal death. Review Question: Does pharmacological therapy decrease either the incidence or severity of disease or infection caused by EHV-1 in domesticated horses? Methods: A systematic review was preformed searching AGRICOLA, CAB Abstracts, Cochrane, PubMed, Web of Science, and WHO Global Health Index Medicus Regional Databases to identify articles published before February 15, 2021. Selection criteria were original research reports published in peer reviewed journals, and studies investigating in vivo use of therapeutic agents for prevention or treatment of EHV-1 in horses. Outcomes assessed included measures related to clinical outcomes that reflect symptomatic EHV-1 infection or virus infection. We evaluated risk of bias and performed a GRADE evaluation of the quality of evidence for interventions. Results: A total of 7009 unique studies were identified, of which 9 met the inclusion criteria. Two studies evaluated valacyclovir or small interfering RNAs, and single studies evaluated the use of a Parapoxvirus ovis-based immunomodulator, human alpha interferon, an herbal supplement, a cytosine analog, and heparin. The level of evidence ranged between randomized controlled studies and observational trials. The risk of bias was moderate to high and sample sizes were small. Most studies reported either no benefit or minimal efficacy of the intervention tested. Conclusions and Clinical Importance: Our review indicates minimal or limited benefit either as a prophylactic or post-exposure treatment for any of the studied interventions in the mitigation of EHV-1-associated disease outcome.


  • Open Access

    Viremia and nasal shedding for the diagnosis of equine herpesvirus-1 infection in domesticated horses

    by Nicola Pusterla, David C. Dorman, Brandy A. Burgess, Lutz Goehring, Margaret Gross, Klaus Osterrieder, Gisela Soboll Hussey, David P. Lunn

    Background: Equine herpesvirus type 1 (EHV-1) infection is associated with upper respiratory disease, EHM, abortions, and neonatal death. Research Questions: Are nasal secretions a more sensitive biological sample compared to blood for the detection of EHV-1 infection? How long is EHV-1 detectable after primary infection by PCR? Methods: MedLine and Web of Science searches identified original peer-reviewed reports evaluating nasal shedding and viremia using virus isolation methods or PCR published in English before October 9, 2023. Results: Sixty experimental and 20 observational studies met inclusion criteria. EHV-1 detection frequency by qPCR in nasal secretions and blood from naturally-infected horses with fever and respiratory signs were 15% and 9%, respectively; qPCR detection rates in nasal secretions and blood from horses with suspected EHM were 94% and 70%, respectively. In experimental studies the sensitivity of qPCR matched or exceeded that seen for virus isolation from either nasal secretions or blood. Detection of nasal shedding typically occurred within 2 days after EHV-1 inoculation with a detection period of 3 to 7 days. Viremia lasted 2 to 7 days and was usually detected ≥1 days after positive identification of EHV-1 in nasal secretions. Nasal shedding and viremia decreased over time and remained detectable in some horses for several weeks after inoculation. Conclusions and Clinical Importance: Under experimental conditions, blood and nasal secretions have similar sensitivity for the detection of EHV-1 when horses are sampled on multiple consecutive days. In contrast, in observational studies detection of EHV-1 in nasal secretions was consistently more successful.


  • Open Access

    Relationship between equine herpesvirus-1 viremia and abortion or equine herpesvirus myeloencephalopathy in domesticated horses: A systematic review

    by Gisela Soboll-Hussey, David C. Dorman, Brandy A. Burgess, Lutz Goehring, Peggy Gross, Claire Neinast, Klaus Osterrieder, Nicola Pusterla, David P. Lunn

    Background: Equine herpes virus type 1 (EHV-1) infection in horses is associated with upper respiratory disease, neurological disease, abortions, and neonatal death. Objective: To determine if there is an association between the level and duration of EHV-1 viremia and either abortion or equine herpesvirus myeloencephalopathy (EHM) in domesticated horses? Methods: A systematic review was performed searching numerous databases to identify peer reviewed reports that evaluated viremia and EHM, or viremia and abortion published before January 19, 2021. Randomized controlled trials and observational studies were assessed for risk of bias or publication quality. Results: A total of 189 unique studies were identified, of which 34 met the inclusion criteria. Thirty studies evaluated viremia and neurologic outcomes including 4 observational studies. Eight experimental studies examined viremia and abortion, which used the Ab4 and OH03 virus strains or recombinant Ab4 derivatives. Incidence rates for both EHM and abortion in experimental studies varied among the studies as did the level of evidence. Viremia was generally detectable before the onset of either EHM or abortion. Risk of bias was generally low to moderate, sample sizes were small, and multiple studies reported negative outcome data. Conclusions and Clinical Importance: The results of this study support that viremia is regularly present before EHM or abortion occurs. However, no inferences could be made about the relationship between the occurrence of either neurological signs or abortion and the magnitude or duration of viremia.


  • Open Access

    Vaccination for the prevention of equine herpesvirus-1 disease in domesticated horses: A systematic review and meta-analysis

    by Klaus Osterrieder, David C. Dorman, Brandy A. Burgess, Lutz S. Goehring, Peggy Gross, Claire Neinast, Nicola Pusterla, Gisela Soboll Hussey, David P. Lunn

    Background: Equine herpes virus type 1 (EHV-1) infection in horses is associated with respiratory and neurologic disease, abortion, and neonatal death. Hypothesis: Vaccines decrease the occurrence of clinical disease in EHV-1-infected horses. Methods: A systematic review was performed searching multiple databases to identify relevant studies. Selection criteria were original peer-reviewed research reports that investigated the in vivo use of vaccines for the prevention of disease caused by EHV-1 in domesticated horses. Main outcomes of interest included pyrexia, abortion, neurologic disease, viremia, and nasal shedding. We evaluated risk of bias, conducted exploratory meta-analyses of incidence data for the main outcomes, and performed a GRADE evaluation of the quality of evidence for each vaccine subtype. Results: A total of 1018 unique studies were identified, of which 35 met the inclusion criteria. Experimental studies accounted for 31/35 studies, with the remainder being observational studies. Eight vaccine subclasses were identified including commercial (modified-live, inactivated, mixed) and experimental (modified-live, inactivated, deletion mutant, DNA, recombinant). Risk of bias was generally moderate, often because of underreporting of research methods, and sample sizes were small leading to imprecision in the estimate of the effect size. Several studies reported either no benefit or minimal vaccine efficacy for the primary outcomes of interest. Meta-analyses revealed significant heterogeneity was present, and our confidence in the quality of evidence for most outcomes was low to moderate. Conclusions and Clinical Importance: Our review indicates that commercial and experimental vaccines minimally reduce the incidence of clinical disease associated with EHV-1 infection.